JP2012521191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521191A5 JP2012521191A5 JP2011551173A JP2011551173A JP2012521191A5 JP 2012521191 A5 JP2012521191 A5 JP 2012521191A5 JP 2011551173 A JP2011551173 A JP 2011551173A JP 2011551173 A JP2011551173 A JP 2011551173A JP 2012521191 A5 JP2012521191 A5 JP 2012521191A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence provided
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 claims 30
- 102000004965 antibodies Human genes 0.000 claims 30
- 102100013135 TNFRSF4 Human genes 0.000 claims 13
- 101710040448 TNFRSF4 Proteins 0.000 claims 13
- 230000003042 antagnostic Effects 0.000 claims 12
- 230000035693 Fab Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 230000001575 pathological Effects 0.000 claims 5
- 102000037240 fusion proteins Human genes 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 102000018358 Immunoglobulins Human genes 0.000 claims 3
- 108060003951 Immunoglobulins Proteins 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000010367 cloning Methods 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102100001249 ALB Human genes 0.000 claims 1
- 101710027066 ALB Proteins 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940050528 albumin Drugs 0.000 claims 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000004676 glycans Polymers 0.000 claims 1
- 229920001427 mPEG Polymers 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 229920002859 polyalkenylene Polymers 0.000 claims 1
- 229920001281 polyalkylene Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 claims 1
Claims (31)
- 重鎖及び軽鎖を含む、ヒトOX40に結合するアンタゴニスト性抗体であって、重鎖可変ドメインが、CDR−H1に関して配列番号1に提供する配列を有するCDR、CDR−H2に関して配列番号2または配列番号20に提供する配列を有するCDR、およびCDR−H3に関して配列番号3に提供する配列を有するCDRを含み、そして、軽鎖可変ドメインが、CDR−L1に関して配列番号4または配列番号21に提供する配列、CDR−L2に関して配列番号5に提供する配列、およびCDR−L3に関して配列番号6に提供する配列を含む、前記抗体。
- 重鎖が配列番号9に提供する配列を含む、請求項1記載の抗体。
- 軽鎖が配列番号7に提供する配列を含む、請求項1又は2記載の抗体。
- 抗体分子が:全長重鎖および軽鎖を有する完全抗体分子あるいはその断片、例えばFab、修飾Fab’、Fab’、F(ab’)2、Fv、VH、VLまたはscFv断片からなる群より選択される、請求項1〜3のいずれか一項記載の中和抗体分子。
- 配列番号9に提供する配列を含む重鎖および配列番号7に提供する配列を含む軽鎖を有する、ヒトOX40に結合するアンタゴニスト性抗体。
- 軽鎖可変ドメインが請求項5の抗体の軽鎖可変ドメインに少なくとも80%の同一性または類似性を有する配列を含み、そして重鎖可変ドメインが請求項5の抗体の重鎖可変ドメインに少なくとも80%の同一性または類似性を有する配列を含む、ヒトOX40に結合するアンタゴニスト性抗体。
- 配列番号15に提供する配列を含む重鎖および配列番号11に提供する配列を含む軽鎖を有する、ヒトOX40に結合するアンタゴニスト性抗体。
- 重鎖および軽鎖が、請求項7の抗体の対応する重鎖および軽鎖に少なくとも80%同一または類似である、ヒトOX40に結合するアンタゴニスト性抗体。
- エフェクターまたはレポーター分子が付着している、請求項1〜8のいずれか一項記載のアンタゴニスト性抗体分子。
- エフェクター分子が1以上のポリマーを含む、請求項9記載のアンタゴニスト性抗体分子。
- 1以上のポリマーが、場合によって置換された直鎖または分枝鎖ポリアルキレン、ポリアルケニレンまたはポリオキシアルキレンポリマー、あるいは分枝または非分枝多糖である、請求項10記載のアンタゴニスト性抗体分子。
- 1以上のポリマーがメトキシポリ(エチレングリコール)またはポリ(エチレングリコール)である、請求項11記載のアンタゴニスト性抗体分子。
- 重鎖のC末端のシステイン残基の1つに付着したリジルマレイミドまたはリジルビスマレイミド基を有する請求項12記載のアンタゴニスト性抗体分子であって、リジル残基の各アミノ基に、20,000Daの分子量を有するメトキシポリ(エチレングリコール)残基が共有結合している、前記抗体分子。
- ヒトOX40に特異性を有するアンタゴニスト性抗体分子であって、配列番号15に提供する配列を含む重鎖および配列番号11に提供する配列を含む軽鎖を有し、そして重鎖の226位のシステインにリジルマレイミド基が付着し、リジル残基の各アミノ基に、20,000Daの分子量を有するメトキシポリ(エチレングリコール)残基が共有結合している、前記抗体分子。
- 請求項1〜14のいずれか一項記載の抗体の重鎖(単数または複数)および/または軽鎖(単数または複数)をコードする単離DNA。
- 請求項15記載の1以上のDNAを含む、クローニングまたは発現ベクター。
- 配列番号14および配列番号18に提供する配列を含む、請求項16記載のベクター。
- 配列番号19に提供する配列を含む、請求項16記載のベクター。
- 請求項16または請求項17または請求項18に記載される1以上のクローニングまたは発現ベクターを含む、宿主細胞。
- 請求項19の宿主細胞を培養し、そして抗体を単離する工程を含む、請求項1〜14のいずれか一項の抗体を産生するための方法。
- 薬学的に許容されうる賦形剤、希釈剤またはキャリアーの1以上と組み合わされた、請求項1〜14のいずれか一項記載の抗体を含む、薬学的組成物。
- 他の活性成分をさらに含む、請求項21記載の薬学的組成物。
- OX40によって仲介されるか、またはOX40レベルの増加と関連する病理学的障害の治療または予防において使用するための、請求項1〜14のいずれか一項記載の抗体、あるいは請求項21または請求項22記載の薬学的組成物。
- OX40によって仲介されるか、またはOX40レベルの増加と関連する病理学的障害の治療または予防のための薬剤製造における、請求項1〜14のいずれか一項記載の抗体の使用。
- OX40に結合する免疫グロブリン部分及び2つのドメイン抗体を含むOX40結合抗体融合タンパク質であって、OX40に結合する免疫グロブリン部分が請求項1記載のアンタゴニスト性抗体である、前記融合タンパク質。
- 免疫グロブリン部分が、FabおよびFab’である、請求項25記載の融合タンパク質。
- 2つのドメイン抗体が、ジスルフィド結合によって連結された、可変重鎖(VH)及び可変軽鎖(VL)対である、請求項25又は26に記載の融合タンパク質。
- VH及びVL対がアルブミンに結合する、請求項27記載の方法。
- 病理学的障害が感染である、請求項24の使用。
- 病理学的障害が移植片対宿主病又は移植拒絶である、請求項24の使用。
- 病理学的障害が、アレルギー、COPD、喘息、自己免疫疾患又は関節リウマチである、請求項24の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15303809P | 2009-02-17 | 2009-02-17 | |
US61/153,038 | 2009-02-17 | ||
PCT/US2010/024377 WO2010096418A2 (en) | 2009-02-17 | 2010-02-17 | Antibody molecules having specificity for human ox40 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015063849A Division JP2015171362A (ja) | 2009-02-17 | 2015-03-26 | ヒトox40に対する特異性を有する抗体分子 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012521191A JP2012521191A (ja) | 2012-09-13 |
JP2012521191A5 true JP2012521191A5 (ja) | 2014-04-17 |
JP5782385B2 JP5782385B2 (ja) | 2015-09-24 |
Family
ID=42634416
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011551173A Expired - Fee Related JP5782385B2 (ja) | 2009-02-17 | 2010-02-17 | ヒトox40に対する特異性を有する抗体分子 |
JP2015063849A Pending JP2015171362A (ja) | 2009-02-17 | 2015-03-26 | ヒトox40に対する特異性を有する抗体分子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015063849A Pending JP2015171362A (ja) | 2009-02-17 | 2015-03-26 | ヒトox40に対する特異性を有する抗体分子 |
Country Status (35)
Country | Link |
---|---|
US (3) | US8614295B2 (ja) |
EP (1) | EP2398498B1 (ja) |
JP (2) | JP5782385B2 (ja) |
KR (1) | KR101761929B1 (ja) |
CN (1) | CN102741287B (ja) |
AR (1) | AR075504A1 (ja) |
AU (1) | AU2010216152B2 (ja) |
BR (1) | BRPI1008692B8 (ja) |
CA (1) | CA2751477C (ja) |
CL (1) | CL2011001994A1 (ja) |
CO (1) | CO6410312A2 (ja) |
CY (1) | CY1121431T1 (ja) |
DK (1) | DK2398498T3 (ja) |
EA (1) | EA037792B1 (ja) |
ES (1) | ES2699716T3 (ja) |
HK (1) | HK1177470A1 (ja) |
HR (1) | HRP20181932T1 (ja) |
HU (1) | HUE042114T2 (ja) |
IL (1) | IL214282A (ja) |
LT (1) | LT2398498T (ja) |
MA (1) | MA33122B1 (ja) |
MX (1) | MX2011008697A (ja) |
MY (1) | MY157473A (ja) |
NZ (1) | NZ594315A (ja) |
PE (1) | PE20120211A1 (ja) |
PL (1) | PL2398498T3 (ja) |
PT (1) | PT2398498T (ja) |
SG (3) | SG10201505038TA (ja) |
SI (1) | SI2398498T1 (ja) |
TN (1) | TN2011000374A1 (ja) |
TW (1) | TWI476281B (ja) |
UA (1) | UA107341C2 (ja) |
UY (1) | UY32451A (ja) |
WO (1) | WO2010096418A2 (ja) |
ZA (1) | ZA201105500B (ja) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA33122B1 (fr) * | 2009-02-17 | 2012-03-01 | Ucb Pharma Sa | Molecules d'anticorps ayant une specificite pour ox40 humain |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
MY171312A (en) * | 2010-08-23 | 2019-10-08 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
WO2013008171A1 (en) | 2011-07-11 | 2013-01-17 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to ox40 and their uses |
AU2012299421B2 (en) * | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
CA2856216C (en) * | 2011-11-11 | 2021-01-12 | Ucb Pharma S.A. | Albumin binding antibodies and binding fragments thereof |
UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
US20130149351A1 (en) * | 2011-12-09 | 2013-06-13 | University Of Southern California | Polymer scaffolds and their use in the treatment of vision loss |
EP3508215A3 (en) | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
SG11201507781VA (en) | 2013-03-18 | 2015-10-29 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
EP3049445A4 (en) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR101844596B1 (ko) * | 2014-03-18 | 2018-04-05 | 한국과학기술원 | 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물 |
CN106132439A (zh) | 2014-03-31 | 2016-11-16 | 豪夫迈·罗氏有限公司 | 包含抗血管发生剂和ox40结合激动剂的组合疗法 |
CA2946398A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
NZ726513A (en) | 2014-05-28 | 2023-07-28 | Memorial Sloan Kettering Cancer Center | Anti-gitr antibodies and methods of use thereof |
TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
CN114504652A (zh) | 2015-03-03 | 2022-05-17 | 科马布有限公司 | 抗体、用途和方法 |
US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
MY188049A (en) | 2015-05-29 | 2021-11-12 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
JP7034066B2 (ja) | 2015-10-02 | 2022-03-11 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激tnf受容体に対する二重特異性抗体 |
US10624974B2 (en) * | 2015-10-15 | 2020-04-21 | Dingfu Biotarget Co., Ltd. | Anti-OX40 antibody and application thereof |
CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
EP3402507A4 (en) | 2016-01-11 | 2019-08-07 | Inhibrx, Inc. | MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS |
WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
DK3347379T5 (da) | 2016-08-17 | 2020-06-15 | Compugen Ltd | Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
WO2018220446A1 (en) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
US11542312B2 (en) | 2017-06-19 | 2023-01-03 | Medicenna Therapeutics, Inc. | IL-2 superagonists in combination with anti-PD-1 antibodies |
JP2021517133A (ja) * | 2018-03-08 | 2021-07-15 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 抗cd252抗体、コンジュゲート、および使用方法 |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
MX2021001703A (es) | 2018-08-13 | 2021-04-19 | Inhibrx Inc | Polipeptidos de union a ox40 y sus usos. |
WO2020070288A1 (en) | 2018-10-05 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
EP3766481A1 (en) * | 2019-07-19 | 2021-01-20 | Ichnos Sciences SA | Liquid antibody formulation |
CA3162705A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
WO2023064958A1 (en) | 2021-10-15 | 2023-04-20 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | 新規な結合タンパク質の生成と選択 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
EP0580737B1 (en) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
GB0123276D0 (en) | 2001-09-27 | 2001-11-21 | Imp College Innovations Ltd | Uses of agents that bind immune-system components |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
GB0124317D0 (en) * | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
AU2002365814A1 (en) | 2001-12-18 | 2003-07-30 | J And J Research Pty Ltd | Method of treating asthma |
US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
EP1570267B1 (en) | 2002-12-03 | 2011-10-12 | UCB Pharma, S.A. | Assay for identifying antibody producing cells |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
PL1644412T5 (pl) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modyfikowane fragmenty Fab przeciwciała |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
CA2528903C (en) * | 2004-12-20 | 2008-01-15 | Honda Motor Co., Ltd. | Braking device for motorcycle |
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
US7850965B2 (en) * | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
WO2007111931A2 (en) | 2006-03-22 | 2007-10-04 | Imperial Innovations Limited | Compositions and methods relating to modulation of immune system components |
WO2007112054A2 (en) * | 2006-03-23 | 2007-10-04 | Sea Lane Biotechnologies, Llc | Facilitation of translocation of molecules through the gastrointestinal tract |
KR20100014588A (ko) * | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
MA33122B1 (fr) | 2009-02-17 | 2012-03-01 | Ucb Pharma Sa | Molecules d'anticorps ayant une specificite pour ox40 humain |
ES2667258T3 (es) * | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) * | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
WO2013008171A1 (en) * | 2011-07-11 | 2013-01-17 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to ox40 and their uses |
UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
-
2010
- 2010-02-17 MA MA34167A patent/MA33122B1/fr unknown
- 2010-02-17 MX MX2011008697A patent/MX2011008697A/es active IP Right Grant
- 2010-02-17 SG SG10201505038TA patent/SG10201505038TA/en unknown
- 2010-02-17 PL PL10744211T patent/PL2398498T3/pl unknown
- 2010-02-17 CA CA2751477A patent/CA2751477C/en active Active
- 2010-02-17 SI SI201031802T patent/SI2398498T1/sl unknown
- 2010-02-17 PE PE2011001494A patent/PE20120211A1/es not_active Application Discontinuation
- 2010-02-17 EA EA201171060A patent/EA037792B1/ru unknown
- 2010-02-17 PT PT10744211T patent/PT2398498T/pt unknown
- 2010-02-17 AR ARP100100457A patent/AR075504A1/es active IP Right Grant
- 2010-02-17 EP EP10744211.3A patent/EP2398498B1/en active Active
- 2010-02-17 DK DK10744211.3T patent/DK2398498T3/en active
- 2010-02-17 JP JP2011551173A patent/JP5782385B2/ja not_active Expired - Fee Related
- 2010-02-17 UA UAA201111078A patent/UA107341C2/uk unknown
- 2010-02-17 KR KR1020117021615A patent/KR101761929B1/ko active IP Right Grant
- 2010-02-17 SG SG2011057528A patent/SG173620A1/en unknown
- 2010-02-17 UY UY0001032451A patent/UY32451A/es not_active Application Discontinuation
- 2010-02-17 US US12/706,993 patent/US8614295B2/en active Active
- 2010-02-17 ES ES10744211T patent/ES2699716T3/es active Active
- 2010-02-17 LT LTEP10744211.3T patent/LT2398498T/lt unknown
- 2010-02-17 HU HUE10744211A patent/HUE042114T2/hu unknown
- 2010-02-17 CN CN201080017854.0A patent/CN102741287B/zh not_active Expired - Fee Related
- 2010-02-17 AU AU2010216152A patent/AU2010216152B2/en not_active Ceased
- 2010-02-17 MY MYPI2011003526A patent/MY157473A/en unknown
- 2010-02-17 NZ NZ594315A patent/NZ594315A/xx not_active IP Right Cessation
- 2010-02-17 BR BRPI1008692A patent/BRPI1008692B8/pt not_active IP Right Cessation
- 2010-02-17 WO PCT/US2010/024377 patent/WO2010096418A2/en active Application Filing
- 2010-02-17 SG SG2014014708A patent/SG2014014708A/en unknown
- 2010-02-22 TW TW099104929A patent/TWI476281B/zh not_active IP Right Cessation
-
2011
- 2011-07-25 IL IL214282A patent/IL214282A/en active IP Right Grant
- 2011-07-26 ZA ZA2011/05500A patent/ZA201105500B/en unknown
- 2011-08-02 TN TN2011000374A patent/TN2011000374A1/fr unknown
- 2011-08-08 CO CO11100099A patent/CO6410312A2/es active IP Right Grant
- 2011-08-16 CL CL2011001994A patent/CL2011001994A1/es unknown
-
2013
- 2013-04-16 HK HK13104585.8A patent/HK1177470A1/xx not_active IP Right Cessation
- 2013-08-22 US US13/973,189 patent/US9428570B2/en active Active
-
2015
- 2015-03-26 JP JP2015063849A patent/JP2015171362A/ja active Pending
-
2016
- 2016-08-19 US US15/242,135 patent/US10017575B2/en active Active
-
2018
- 2018-11-20 HR HRP20181932TT patent/HRP20181932T1/hr unknown
- 2018-12-04 CY CY20181101288T patent/CY1121431T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012521191A5 (ja) | ||
AU2019205981B2 (en) | Multispecific antibody constructs | |
HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
JP2019151634A5 (ja) | ||
JP2009225799A5 (ja) | ||
JP2019515646A5 (ja) | ||
JP2011527902A5 (ja) | ||
JP2011504501A5 (ja) | ||
JP2019533719A5 (ja) | ||
JP2012501670A5 (ja) | ||
RU2018146158A (ru) | Антитела | |
JP2017533694A5 (ja) | ||
JP2016529882A5 (ja) | ||
JP2013545455A5 (ja) | ||
JP2015519375A5 (ja) | ||
JP2012501669A5 (ja) | ||
JP2009540855A (ja) | ヒトil−17に結合する抗体分子 | |
JP2012500020A5 (ja) | ||
JP2016519124A5 (ja) | ||
JP2011527899A5 (ja) | ||
JP2014529610A5 (ja) | ||
JP2010501164A5 (ja) | ||
JP2015517492A5 (ja) | ||
JP2019505565A5 (ja) | ||
JP2016006052A5 (ja) |